-+ 0.00%
-+ 0.00%
-+ 0.00%

Immix Biopharma Advances NXC-201 Cell Therapy In AL Amyloidosis And Other Serious Diseases; Plans To Out-License OSD Programs

Benzinga·08/06/2025 16:32:21
Listen to the news

– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) –

Company plans to partner-out Other Serious Disease programs –

–  On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/refractory AL Amyloidosis

LOS ANGELES, CA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced important updates about its plan to address other serious diseases with its sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a "digital filter" that filters out non-specific activation. The Company plans to release forthcoming clinical data at upcoming scientific forums.